Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Malaria --- Parasitic Diseases --- Disease Vectors. --- Insect Vectors. --- Malaria. --- prevention & control. --- India. --- Health Sciences --- Clinical Medicine --- vector borne diseases --- malaria --- filaria --- Japanese encephalitis --- dengue --- chikungunya --- japanese encephalitis --- Infectious diseases. Communicable diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The One Health concept recognizes that the health of humans, animals, and their ecosystems are interconnected, and that a coordinated, collaborative, multidisciplinary, and cross-sectoral approach is necessary to fully understand and respond to potential or existing risks that originate at the animal–human–ecosystems interfaces. Thus, the One Health concept represents a holistic vision for addressing some of the complex challenges that threaten human and animal health, food safety, and the environments in which diseases flourish. There are many examples showing how the health of humans is related to the health of animals and the environment. Diseases shared between humans and animals are zoonoses. Some zoonoses have been known for many years, whereas others have emerged suddenly and unexpectedly. Over 70% of all new emerging diseases over the past few decades have been zoonoses that have emerged from wildlife, most often from bats, rodents, or birds. Examples of zoonoses are many and varied, ranging from rabies to bovine tuberculosis, and from Japanese encephalitis to SARS. Clearly, a One Health approach is essential for understanding their ecology, and for outbreak response and the development of control strategies. However, the One Health concept and approach is much broader than zoonoses; it extends to including antimicrobial resistance, food safety, and environmental health and, consequently, impacts on global health security, economic wellbeing, and international trade. It is this breadth of One Health that connects the papers in this Special Issue.

n/a --- descriptive epidemiology --- antimicrobials --- real-time PCR --- guinea pigs --- pandemic --- vector-borne disease --- Ebola virus --- transmission --- antimicrobial resistance --- serology --- microbats --- smallholder farming --- WHO --- AMR --- Clostridium difficile --- zoonoses --- water --- zoonosis --- scrub typhus --- Q fever --- emerging disease --- antibiotics --- clinical pattern --- food chain --- influenza --- pyrogenicity --- Western Australia --- Brucella abortus --- Luminex --- epidemiology --- Joint External Evaluation (JEE) --- prevalence --- Performance of Veterinary Services (PVS) --- World Trade Organization (WTO) --- urban livestock keeping --- surveillance --- human --- C. burnetii --- Australian bat lyssavirus --- One Health --- wildlife --- emerging infectious diseases --- mosquito --- Codex --- international health regulations --- swine --- environment --- trade --- Asia --- infrastructure --- Japanese encephalitis virus --- Australia --- incidence

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, and influenza viruses. Despite the successes of these antiviral drugs, issues with drug resistance and toxicity remain challenging. These challenges are driving research to identify new drug candidates and to investigate novel drug targets to develop new mechanistic drug classes. Antiviral agents are not available against many viruses that cause human disease and economic burdens; in particular, the development of antiviral agents against emerging, re-emerging, and neglected viruses is increasingly becoming a priority. This book includes six review articles that discuss new antiviral strategies. The reviews either discuss advances relating to a specific virus or new therapeutic targets and approaches. The book includes 15 original research articles reporting new antiviral agents against a variety of clinically and economically important viruses and studies into the prevalence or acquisition of drug resistance. Overall, this book is an exciting collection of new research and ideas relating to the development of antiviral agents.

Zika virus --- nucleoside analogues --- antiviral agents --- NS5 --- prodrugs --- ProTides --- neural stem cells --- RNA-dependent RNA polymerase --- cytomegalovirus --- latent infection --- TALEN --- Surveyor nuclease mutation detection assay --- ie-1 gene --- quantitative real-time PCR --- Epstein–Barr virus --- herpes viruses --- lytic gene expression --- Burkitt lymphoma cells --- clozapine --- antipsychotic drug --- antiviral drug --- enteroviruses --- coxsackievirus B4 --- persistent infection --- fluoxetine --- resistance --- mutations --- herpes B virus --- macacine herpesvirus-1 --- genistein --- flavonoids --- acyclovir --- ganciclovir --- Plantago asiatica --- Clerodendrum trichotomum --- RSV --- therapeutic effects --- acteoside --- human antimicrobial peptides --- antiviral strategies --- defensins --- cathelicidins --- hepcidins --- transferrins --- influenza A virus --- brevilin A --- antiviral --- sesquiterpene lactone --- replication --- PRRSV --- polyethylenimine --- PEI --- virion internalization --- endocytosis --- HIV --- pediatrics --- Ethiopia --- pre-treatment drug resistance --- combination antiretroviral therapy (cART) --- dried plasma spots --- dried blood spots --- sphingolipids --- glycosphingolipids --- viruses --- lipid biosynthesis --- flavivirus --- Japanese encephalitis virus --- furin inhibitor --- precursor membrane protein --- measles virus --- central nervous system --- tropism --- treatments --- porcine reproductive and respiratory syndrome virus --- ginsenoside Rg1 --- antiviral activity --- pro-inflammatory factor --- NF-κB signaling pathway --- acute/latent infection --- congenital infection --- antiviral agent --- therapeutic strategies --- nucleic acid-based therapeutic approach --- HCMV vaccine --- adoptive cell therapy --- Rev response element --- chemical footprinting --- SHAPE --- drug discovery --- branched peptides --- herpesvirus --- immediate-early --- IE1 --- IE2 --- ribozyme --- RNA interference --- CRISPR/Cas --- small molecule --- orthohantavirus --- phenyl-benzotriazoles --- C-FRA --- Porcine circovirus type 2 --- epigallocatechin gallate --- heparan sulfate --- antiviral effect --- virus attachment --- microvirin --- lectin --- human immunodeficiency virus --- hepatitis C virus --- antiviral inhibitor --- non-immunogenic --- viral entry --- protein drugs --- LUMS1 --- oleanane-type derivatives --- influenza A virus (IAV) --- virus entry inhibitors --- hemagglutinin (HA) --- n/a --- Epstein-Barr virus